Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a Trend in Both Cancer Gene Therapy and Cancer Virotherapy

Author(s): Xin -Yuan Liu, Hua -Guang Li, Kang -Jian Zhang, Jin -Fa Gu

Journal Name: Current Pharmaceutical Biotechnology

Volume 13 , Issue 9 , 2012

Become EABM
Become Reviewer


Cancer Targeting Gene-Viro-Therapy (CTGVT) and Gene Armed Oncolytic Virus Therapy (GAOVT) both are identical by inserting an antitumor gene into an oncolytic virus. This approach has gradually become a hot topic in cancer therapy, because that CTGVT (GAOVT) has much higher antitumor than that of either gene therapy alone or oncolytic virotherapy alone. We proposed the CTGVT strategy in 1999-2001, insisted it as a long term systematic approach to be examined over 10 years and have published 68 SCI papers some in good Journals. The CD gene armed oncolytic adenovirus therapy (GAOVT) for cancer treatment with potent antitumor effect was also named in our laboratory in 2003. Several modifications to CTGVT will be carried out by our group and will be introduced briefly in this paper. Most importantly, the modifications of CTGVT usually resulted in complete eradication of xenograft tumors in nude mice. In future best antitumor drugs may emerge from the modified CTGVT strategy and not from either gene therapy or virotherapy alone.

Keywords: Cancer therapy, Cancer targeting, Gene Viro-Therapy, Trend of gene therapy, Trend of virotherapy, Gene Armed Oncolytic Virus Therapy (GAOVT), oncolytic virotherapy, cancer, xenograft tumors, melanoma

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 13 June, 2012
Page: [1761 - 1767]
Pages: 7
DOI: 10.2174/138920112800958869
Price: $65

Article Metrics

PDF: 16